Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome
Jin Lu, Albert Oriol, Alejandro Berkovits, Andrew Spencer, César Cinesi Gómez, Chunrui Li, Claudio Cerchione, Fei Li, Fredrik Schjesvold, Gurdeep Parmar, Ivan Špıčka, Marek Hus, Maria Del Rosario Custidiano, Meletios A Dimopoulos, Péter Rajnics, Sevgi Kalayoğlu Beşışık, Sikander Ailawadhi, Silvia Ling, Vânia Hungria, Xavier Leleu, Florence Suzan Teisserenc, Maya Stefanova-Urena, Rick Zhang, Victorine Koch, Dorothée Sémiond (2025). Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome. , 146(Supplement 1), DOI: https://doi.org/10.1182/blood-2025-5812.
